Luis Polo, NP
Nurse Practitioner · Savannah, GANPI 1831624899
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,400 of the $69,813 with a category attached, or 66.5%. 30 manufacturers reported payments, led by AstraZeneca at 45.9% of the total. Reporting peaked in 2023 at $22,968 and has fallen 70.3% since, to $6,829 in 2025. Among nurse practitioner clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 406 payments — averaging $171.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$32K
- Amgen$31K
- Vifor Pharma, Inc.$944
- Aurinia Pharma U.S., Inc.$922
- Mallinckrodt Hospital Products Inc.$920
- Otsuka America Pharmaceutical, Inc.$509
- plus $3K from 24 others
What the payments were for
- Consulting fees$2,3003%
- Speaking & faculty fees$46,40066%
- Travel & lodging$9,90014%
- Food & beverage$10,67115%
- Education$5421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 89 | $32,025 |
| Amgen(2 entities) | 96 | $31,074 |
| Vifor Pharma, Inc. | 22 | $944 |
| Aurinia Pharma U.S., Inc. | 24 | $922 |
| Mallinckrodt Hospital Products Inc. | 30 | $920 |
| Otsuka America Pharmaceutical, Inc. | 17 | $509 |
| Ardelyx, Inc. | 14 | $500 |
| Travere Therapeutics, Inc. | 16 | $466 |
| Bayer | 26 | $430 |
| Novartis | 5 | $251 |
| Averitas Pharma Inc. | 8 | $231 |
| OPKO Pharmaceuticals, LLC | 6 | $228 |
| Calliditas Therapeutics US Inc. | 10 | $177 |
| Novo Nordisk | 4 | $170 |
| Boehringer Ingelheim | 7 | $137 |
| Baxter Healthcare | 1 | $128 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $109 |
| Pharmacosmos Therapeutics Inc. | 6 | $96 |
| Fresenius USA Marketing, Inc. | 4 | $86 |
| Akebia Therapeutics Inc | 3 | $62 |
| Lilly USA, LLC | 3 | $62 |
| Galderma Laboratories, L.p. | 3 | $56 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| GSK | 2 | $39 |
| Cormedix Inc. | 2 | $38 |
| Nevro Corp. | 1 | $29 |
| Cvrx, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Leadiant Biosciences, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,813 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 18 | $67,852 |
| FarxigaDapagliflozin Propanediol | 51 | $51,359 |
| KerendiaFinerenone | 36 | $38,113 |
| RayaldeeCalcifediol | 21 | $29,126 |
| MounjaroTirzepatide | 13 | $15,307 |
| Sevelamer Carbonate | 35 | $7,620 |
| Colchicine | 15 | $1,011 |
| Nebivolol Hcl | 27 | $982 |
| Midodrine Hcl | 15 | $968 |
| Calcitriol | 21 | $474 |
| Telmisartan | 24 | $461 |
| Chlorthalidone | 26 | $444 |
| Amlodipine Besylate | 63 | $431 |
| Nifedipine ErNifedipine | 21 | $426 |
| Minoxidil | 22 | $400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $32,025 | $51,35951 claims |
| BayerKerendia | $430 | $38,11336 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $228 | $29,12621 claims |
| Lilly USA, LLCMounjaro | $62 | $15,30713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Savannah
- Jessica AdkinsSavannah$226K
- Wallette WidenerSavannah$20K
- Angie MoyeSavannah$14K
- Amy CarterSavannah$11K
- Mary RockwellSavannah$9K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$221K
- Laura ElledgeAtlanta$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.